BACKGROUND: Releasing drug molecules at the targeted location could increase the clinical outcome of a large number of anti- @entity5 treatments which require low systemic damage and low side effects. Nano-carriers of drugs show great potential for such task due to their capability of accumulating and releasing their payload specifically, at the @entity5 site. RESULTS: @entity7801 inhibitor - gold nanoparticle conjugates were fabricated to serve as vehicles for the delivery of anti- @entity5 drugs. @entity39718 , @entity25293 , @entity2857 , and @entity42403 were selected among the @entity7801 inhibitor drugs that are currently used in clinics for the treatment of @entity3052 . The drugs were loaded onto nanoparticle surface using a conjugation strategy based on hydrophobic-hydrophobic interactions with the @entity28174 co-polymer used as nanoparticle surface coating. Optical absorption characterization of the particles in solution showed that @entity7801 inhibitor-incorporated gold nanoparticles were uniformly distributed and chemically stable regardless of the drug content. Drug loading study revealed a high drug content in the case of @entity25293 drug which also showed increased stability. Drug release test in simulated @entity5 cell conditions demonstrated more than 56  % release of the entrapped drug, a result that correlates well with the superior @entity137 of the nano-conjugates comparatively with the free drug. CONCLUSIONS: This is a pioneering study regarding the efficient loading of gold nanoparticles with selected @entity7801 inhibitors. In vitro @entity137 assessment shows that @entity7801 -incorporated gold nanoparticles are promising candidates as vehicles for anti- @entity5 drugs and demonstrate superior therapeutic effect comparatively with the bare drugs.

Design of XXXX Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of @entity3052 .

@entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity25293 :: ('MESH:C059539', 'Chemical') :: ['midostaurin'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity28174 :: ('CHEBI:53514', 'Chemical') :: ['Pluronic'] @entity7801 :: ('2322', 'Gene') :: ['FLT3'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia'] @entity39718 :: ('MESH:C119379', 'Chemical') :: ['Lestaurtinib'] @entity42403 :: ('MESH:C544967', 'Chemical') :: ['quizartinib']
@entity7801 :: (2322,Gene) :: ['FLT3']
